Contraceptive introduction and the management of choice: the role of Cyclofem in Indonesia.
This paper presents a programmatic perspective on the relationship between the introduction of new contraceptive technology and expanding contraceptive options, using the example of Cyclofem in Indonesia. Past approaches to contraceptive introduction have considered only the characteristics of the new method in the decision-making process. In assessing whether the introduction of a new method actually expands contraceptive choice for women and whether the program has the managerial capabilities to assure quality of care in this process, the authors argue that consideration must be given to all methods within a delivery system and how new technology relates to the management of contraceptive choice. Using this perspective, the authors suggest that choice would not necessarily be expanded with scaled-up service delivery of a new once-a month injectable in the Indonesian public sector context.
Simmons
R
R
Department of Population Planning and International Health, School of Public Health, University of Michigan, Ann Arbor 48109-2029.
Fajans
P
P
Lubis
F
F
D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage; D003692:Delayed-Action Preparations; D003695:Delivery of Health Care; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005193:Family Planning Services; D005260:Female; D006801:Humans; D007214:Indonesia; D007267:Injections; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate